• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

FDA sets date for high-profile CAR-T adcomm for Bristol's Abecma, J&J's Carvykti

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 04, 2024 at 12:42: PM
via Mark your calendars, oncology drug and CAR-T therapy developers. The FDA has decided on a date for a highly anticipated advisory committee meeting to discuss applications for Bristol Myers Squibb's Abecma and Johnson & Johnson's Carvykti.

article source
 

<



Similar threads

cafead
FDA accepts Eisai&#039;s subcutaneous Leqembi filing, sets January 25 decision date
Replies
0
Views
9
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA sets advisory meeting date for Brainstorm’s ALS cell therapy
Replies
0
Views
124
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA sets July decision date for full approval of Leqembi
Replies
0
Views
297
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA sets August decision date for Provention’s type 1 diabetes drug
Replies
0
Views
169
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA sets April date for verdict on Incyte’s vitiligo drug
Replies
0
Views
201
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote